A very active SBIR player in the early days of the program, in 1993, Verax was acquired by Creative BioMolecules, itself an active SBIR Awardee. Creative BioMolecules has subsequently merged with another SBIR firm and with a third firm (not SBIR-involved) to found the publicly traded entity Curis.